LON:CLL - Cello Health Share Price, Forecast & News

Cello Health trades on the London Stock Exchange (LON) under the ticker symbol "CLL."

Cello Health announced a dividend on Wednesday, September 18th. Shareholders of record on Thursday, October 3rd will be given a dividend of GBX 1.15 per share on Friday, November 1st. This represents a yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 3rd. The official announcement can be seen at this link. View Cello Health's Dividend History.

1 equities research analysts have issued twelve-month target prices for Cello Health's shares. Their forecasts range from GBX 135 to GBX 160. On average, they anticipate Cello Health's stock price to reach GBX 147.50 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for Cello Health.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cello Health in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cello Health.

News stories about CLL stock have been trending very negative on Tuesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cello Health earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Cello Health.

Some companies that are related to Cello Health include QMS Media (QMS), IVE Group (IGL), Wellcom Group (WLL), Tremor International (TRMR), Taptica International (TAP), GTN (GTN), Salmat (SLM), cbdMD (YCBD), Trimantium Growthops (TGO), NAHL Group (NAH), I Synergy Group (IS3), Ebiquity (EBQ), Arena Events Group (ARE), System1 Group (SYS1) and Tech Mpire (TMP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cello Health investors own include Lloyds Banking Group (LLOY), Optimer Pharmaceuticals (OPTR), Gilead Sciences (GILD), Sirius Minerals (SXX), Saga (SAGA), QinetiQ Group (QQ), Modern Water (MWG), IGAS Energy (IGAS), ICAP (IAP) and easyJet (EZJ).

Shares of CLL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of CLL stock can currently be purchased for approximately GBX 129.

Cello Health has a market capitalization of £137.04 million and generates £167.91 million in revenue each year. View Additional Information About Cello Health.

The official website for Cello Health is http://www.cellogroup.com/.

Cello Health's mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company can be reached via phone at +44-20-78128460.